Insider Buying Confirms Confidence: David Hochman’s New OBIO Purchase Boosts Investor Trust
Orchestra BioMed insider activity shows steady executive confidence: Hochman’s routine RSU sell highlights stability amid 52‑week highs, 135% YTD gains and a discounted valuation – a sign of long‑term upside.
3 minutes to read